| TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year |
PALO ALTO, Calif.--(BUSINESS WIRE)--Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company. The list recognizes and honors the top 100 most influential people in global health this year. “The inclusion on TIME100 Health's list is more than a personal honor,” said AmirAli Talasaz, Guardant Health co-CEO. “It is a recognition of the incredible technology that our Guardant team has buil. |
businesswire.com |
2025-05-08 13:20:00 |
Czytaj oryginał (ang.) |
| Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 157,466 shares of its common stock to 139 new non-executive employees and two non-qualified stock option awards to purchase 19,295 shares of its common stock to two new non-executive employees with a grant date of May 2. |
businesswire.com |
2025-05-07 21:05:00 |
Czytaj oryginał (ang.) |
| Guardant Health: Tailwinds Are Beginning To Impact The Financials |
Guardant Health handily beat Q1 expectations and meaningfully increased full-year growth expectations. Guardant also continues to benefit from positive developments in relation to pricing, regulatory approval, reimbursement coverage, and study data. I expect Guardant's fundamentals to continue strengthening in coming quarters, which should lead its stock price higher. |
seekingalpha.com |
2025-05-01 20:33:27 |
Czytaj oryginał (ang.) |
| Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript |
Guardant Health, Inc. (NASDAQ:GH ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Chairman and Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Michael Bell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Tycho Peterson - Jefferies Bill Bonello - Craig-Hallum Subbu Nambi - Guggenheim Partners Puneet Souda - Leerink Partners Dan Leonard - UBS Dan Brennan - TD Cowen Rachel Vatnsdal - JPMorgan Luke Sergott - Barclays Operator Hello, everybody and welcome to the Guardant Health Q1 2025 Earnings Call. My name is Elliot, and I will be your coordinator today. |
seekingalpha.com |
2025-05-01 02:25:41 |
Czytaj oryginał (ang.) |
| Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates |
Guardant Health (GH) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.46 per share a year ago. |
zacks.com |
2025-04-30 22:55:58 |
Czytaj oryginał (ang.) |
| Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25%. |
businesswire.com |
2025-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its methylation-based Shield™ multi-cancer detection (MCD) test demonstrated high specificity and clinically meaningful sensitivity across ten tumor types,* while also providing information to guide clinical diagnostic evaluation. The study was presented at the 2025 American Association for Cancer Research (AACR) annual meeting. Results of. |
businesswire.com |
2025-04-29 20:20:00 |
Czytaj oryginał (ang.) |
| CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer |
PALO ALTO, Calif.--(BUSINESS WIRE)--Throughout release, "exome-wide" should read as "genome-wide". The updated release reads: GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer genome-wi. |
businesswire.com |
2025-04-28 13:12:00 |
Czytaj oryginał (ang.) |
| Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Guardant360® Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis—including DNA, RNA, AI-powered PD-L1 and exome-wide methylation data—to provide researchers and cancer care teams with a more comprehensive view of cancer. Powered by the Guardant Infinity™ smart liquid biopsy platform, the advanced G. |
businesswire.com |
2025-04-28 12:05:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline |
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-23 15:07:52 |
Czytaj oryginał (ang.) |
| Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, including four oral sessions, showcasing advances in multi-cancer detection and multiomic precision oncology testing enabled by its Guardant Infinity™ smart liquid biopsy platform at the 2025 American Association for Cancer Research (AACR) Annual Meeting, April 25-30 in Chicago. Key data that will be highlighted include: An oral presentation. |
businesswire.com |
2025-04-22 12:05:00 |
Czytaj oryginał (ang.) |
| Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025 |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will. |
businesswire.com |
2025-04-10 20:05:00 |
Czytaj oryginał (ang.) |
| Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has entered into an agreement with Bayshore HealthCare, a leading home and community healthcare service provider in Canada, to offer Guardant's portfolio of precision oncology tests across the continuum of cancer care through the Bayshore network of clinics in Canada. Bayshore HealthCare provides care to over 350,000 Canadians annually (excluding Quebec), and the agre. |
businesswire.com |
2025-04-03 12:05:00 |
Czytaj oryginał (ang.) |
| 4 Healthcare Stocks With Massive Gains—and More to Come |
The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks are doing exceptionally well, outperforming the general market as the most successful sector of 2025 so far. |
marketbeat.com |
2025-03-29 09:16:26 |
Czytaj oryginał (ang.) |
| Guardant Health's Shield Blood Test Now Covered for VA Community Care Beneficiaries |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covered by a key healthcare insurance program for U.S. veterans. The screening test is covered for patients receiving community care authorized by the U.S. Department of Veterans Affairs (VA) as an in-network benefit, with no copay for average-risk individuals who are age 45 or older. Following Medicare. |
businesswire.com |
2025-03-25 18:05:00 |
Czytaj oryginał (ang.) |
| Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation |
Guardant Health basically leads in liquid biopsy oncology diagnostics using genomic and digital technologies for early cancer detection. One of its main offerings is Guardant360, which is currently generating record revenues and growth for GH. Similarly, GH has an expanding pipeline, which includes its Reveal and Shield tests, that could significantly boost its future market potential. |
seekingalpha.com |
2025-03-13 09:51:17 |
Czytaj oryginał (ang.) |
| Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue |
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.'s GH Shield blood test for colorectal cancer (CRC) screening. |
benzinga.com |
2025-03-11 16:48:25 |
Czytaj oryginał (ang.) |
| Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 110,681 shares of its common stock to 102 new non-executive employees and one non-qualified stock option award to purchase 22,091 shares of its common stock to one new non-executive employee with a grant date of Febr. |
businesswire.com |
2025-02-28 19:05:00 |
Czytaj oryginał (ang.) |
| New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of the second annual “Closing the Gap: CRC Screening Insights” survey, which showed that nine out of ten physicians surveyed are concerned about the percentage of their patients who do not complete colorectal cancer (CRC) screening. In many cases, this is due to patient fear and anxiety, but a blood test option offers hope to increase screening rates. Conduct. |
businesswire.com |
2025-02-27 10:05:00 |
Czytaj oryginał (ang.) |
| Is Guardant Health (GH) Outperforming Other Medical Stocks This Year? |
Here is how Guardant Health (GH) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year. |
zacks.com |
2025-02-25 12:41:03 |
Czytaj oryginał (ang.) |
| What's Going On With Cancer Diagnostic Firm Guardant Health On Friday? |
On Thursday, Guardant Health GH reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, beating the consensus loss of 74 cents. |
benzinga.com |
2025-02-21 15:33:38 |
Czytaj oryginał (ang.) |
| Guardant Health, Inc. (GH) Q4 2024 Earnings Call Transcript |
Call Start: 16:30 January 1, 0000 5:31 PM ET Guardant Health, Inc. (NASDAQ:GH ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President, IR Helmy Eltoukhy - Co-Chief Executive Officer AmirAli Talasaz - Co-Chief Executive Officer Mike Bell - Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Bill Bonello - Craig-Hallum Tycho Peterson - Jefferies Dan Brennan - TD Cowen Subbu Nambi - Guggenheim Mark Massaro - BTIG Patrick Donnelly - Citi Dan Arias - Stifel Tejas Savant - Morgan Stanley Rachel Vatnsdal - JPMorgan Kyle Mikson - Canaccord Mason Carrico - Stephens Inc. Matt Sykes - Goldman Sachs Operator Good afternoon. Thank you for attending today's Guardant Health Q4 2024 Earnings Call. |
seekingalpha.com |
2025-02-21 01:14:00 |
Czytaj oryginał (ang.) |
| Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say |
The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-20 21:30:31 |
Czytaj oryginał (ang.) |
| Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates |
Guardant Health (GH) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $1.58 per share a year ago. |
zacks.com |
2025-02-20 20:40:28 |
Czytaj oryginał (ang.) |
| Guardant Health Tops Q4 Revenue Forecast |
Guardant Health (GH -3.26%), a leader in precision oncology testing, announced its fourth-quarter results on Feb. 20. Total revenue rose 30% year over year to $201.8 million, outpacing analysts' consensus estimates of $192 million. |
fool.com |
2025-02-20 19:54:50 |
Czytaj oryginał (ang.) |
| Exploring Analyst Estimates for Guardant Health (GH) Q4 Earnings, Beyond Revenue and EPS |
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Guardant Health (GH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024. |
zacks.com |
2025-02-17 12:20:37 |
Czytaj oryginał (ang.) |
| Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher? |
Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-13 13:07:14 |
Czytaj oryginał (ang.) |
| These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar |
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. |
zacks.com |
2025-02-13 11:51:26 |
Czytaj oryginał (ang.) |
| Guardant Health: Asymptomatic Screening Creating An Asymmetric Opportunity |
Blood-based cancer testing presents a large opportunity, that is now being realized, with the proliferation of MRD and screening tests. While there is significant competition, and the market winners are yet to be determined, Guardant Health is well positioned. Guardant has faced skepticism due to its large losses and the questionable efficacy of blood-based CRC screening tests. |
seekingalpha.com |
2025-02-13 11:45:24 |
Czytaj oryginał (ang.) |
| Here's Why Guardant Health (GH) Is a Great 'Buy the Bottom' Stock Now |
After losing some value lately, a hammer chart pattern has been formed for Guardant Health (GH), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
zacks.com |
2025-02-11 12:56:21 |
Czytaj oryginał (ang.) |
| Guardant Health to Participate in Upcoming Investor Conferences |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT Hosting 1x1 meetings on Tuesday, February 11th and Wednesday, February 12th TD Cowen 45th Annual Health Care Conference in Boston, MA Fireside chat on Tuesday, March 4th at 10:30 a.m. Eastern Tim. |
businesswire.com |
2025-02-10 09:00:00 |
Czytaj oryginał (ang.) |
| Guardant Health Announces Debt Exchange Transactions |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 6, 2025, it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its outstanding 0% Convertible Senior Notes due 2027 (the “2027 Notes”), pursuant to which the Company will issue $600 million aggregate principal amount of 1.25% Convertible Senior Notes due 2031 (the “New Notes”) in exchange for the ret. |
businesswire.com |
2025-02-07 08:30:00 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging Guardant Health (GH) This Year? |
Here is how Guardant Health (GH) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year. |
zacks.com |
2025-02-06 12:40:52 |
Czytaj oryginał (ang.) |
| Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025 |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. |
businesswire.com |
2025-01-30 18:05:00 |
Czytaj oryginał (ang.) |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now |
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP. |
zacks.com |
2025-01-28 11:56:37 |
Czytaj oryginał (ang.) |
| Guardant Health to Present Data at ASCO GI Demonstrating the Value of Its Precision Oncology Tools for Cancer Detection, Treatment Decisions and Therapy Development |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data showcasing the benefits of Guardant's precision oncology tools across cancer screening, recurrence monitoring, treatment selection and therapy development at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, January 23-25, 2025. Key focus areas in Guardant'. |
businesswire.com |
2025-01-23 10:05:00 |
Czytaj oryginał (ang.) |
| Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test |
On Tuesday, Guardant Health, Inc. GH announced that Palmetto GBA, a Medicare administrative contractor that administers the Molecular Diagnostics Services program (MolDX), granted coverage for the Guardant Reveal test to monitor for disease recurrence in patients with colorectal cancer (CRC) following curative intent therapy. |
benzinga.com |
2025-01-21 16:15:13 |
Czytaj oryginał (ang.) |
| Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone |
Guardant Health stock hit a 13-month high Tuesday after Medicare officials agreed to pay for the company's colon cancer blood test. The post Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone appeared first on Investor's Business Daily. |
investors.com |
2025-01-21 13:51:36 |
Czytaj oryginał (ang.) |
| Guardant Health to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Guardant Health's management is scheduled to present and participate in a Q&A session on Monday, January 13, at 4:30 p.m. Pacific Time / 7:30 p.m. Eastern Time. Interested parties may access live and archived webcasts of the sessions on the “Investors” section. |
businesswire.com |
2025-01-02 18:05:00 |
Czytaj oryginał (ang.) |
| Meaningful Insights Biotech Analytics (MiBA) and Guardant Health Announce Strategic Partnership to Optimize Use of Biomarker Testing and Data Analytics to Improve Cancer Care |
PALO ALTO, Calif. & TAMPA, Fla.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Meaningful Insights Biotech Analytics (MiBA), an innovative healthcare technology company, today announced a unique partnership aimed at optimizing the use of biomarker testing and data analytics to advance precision medicine in patient care throughout the MiBA Network. Recognizing the evolving landscape of precision medicine, the collaboration combines MiBA's cutting-. |
businesswire.com |
2024-12-20 10:05:00 |
Czytaj oryginał (ang.) |
| COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics |
NEW YORK--(BUSINESS WIRE)--COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of COTA's research-grade electronic health record (EHR) data from academic and community care centers and Guardant's clinicogenomic testing data to accelerate the development of new cancer therapies. Using the extensiv. |
businesswire.com |
2024-12-19 08:00:00 |
Czytaj oryginał (ang.) |
| Guardant Health Announces Collaboration With Boehringer Ingelheim to Develop Companion Diagnostic for Detection of Specific Mutations in Advanced Lung Cancer |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a collaboration with Boehringer Ingelheim to pursue the regulatory approval and commercialization of the Guardant360® CDx liquid biopsy as a companion diagnostic (CDx) for zongertinib, an investigational covalent tyrosine kinase inhibitor (TKI) that selectively inhibits HER2 while sparing epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC). As p. |
businesswire.com |
2024-12-18 10:05:00 |
Czytaj oryginał (ang.) |
| Guardant Health to Share New Research Demonstrating Value of Liquid Biopsy Tests, Real-world Data and AI Analytics in Tailoring Treatment Approaches for Breast Cancer at 2024 San Antonio Breast Cancer Symposium |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data demonstrating the benefits of its precision oncology tests, real-world clinical-genomic database and AI analytics in optimizing therapy selection, identifying resistance mutations, and predicting long-term outcomes at the San Antonio Breast Cancer Symposium (SABCS) 2024 in San Antonio, Texas, Dec. 10-13, 2024. |
businesswire.com |
2024-12-09 10:05:00 |
Czytaj oryginał (ang.) |
| Guardant Health Stock Flashing Surefire ‘Buy' Signal |
Biotechnology stock Guardant Health (GH) is trading at 15-month highs today, last seen up 7% at $38.28. Shares have added 107.7% over the last nine months, and now stand nearly 42% higher in 2024. |
forbes.com |
2024-12-04 15:31:35 |
Czytaj oryginał (ang.) |
| Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™ |
Guardant Health Secures One of the Largest False Advertising Verdicts in History, Representing a Significant Victory for Colorectal Cancer Patients Who Could Benefit from Guardant Reveal™ Natera Found to Have Willfully Misled Oncologists in an Effort to Thwart Competition PALO ALTO, Calif. , Nov. 25, 2024 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH) ("Guardant Health"), a leading precision oncology company, today announced that a jury in the U.S. District Court for the Northern District of California (the "Court") unanimously found in favor of Guardant Health on all of its claims from its May 2021 lawsuit against Natera, Inc. (Nasdaq: NTRA) ("Natera") for false advertising and unfair competition. |
prnewswire.com |
2024-11-25 19:09:00 |
Czytaj oryginał (ang.) |
| Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 233,603 shares of its common stock to 123 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 50,349 shares of its common stock to three new non-executive employees with a gra. |
businesswire.com |
2024-11-13 19:05:00 |
Czytaj oryginał (ang.) |
| Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought |
The rock star money manager is starting to roll with the rallying market. |
fool.com |
2024-11-12 13:55:00 |
Czytaj oryginał (ang.) |
| Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript |
Guardant Health, Inc. (GH) Q3 2024 Earnings Call Transcript |
seekingalpha.com |
2024-11-06 23:53:40 |
Czytaj oryginał (ang.) |
| Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates |
Although the revenue and EPS for Guardant Health (GH) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2024-11-06 23:00:48 |
Czytaj oryginał (ang.) |
| Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates |
Guardant Health (GH) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.73 per share a year ago. |
zacks.com |
2024-11-06 21:21:29 |
Czytaj oryginał (ang.) |
| Unveiling Guardant Health (GH) Q3 Outlook: Wall Street Estimates for Key Metrics |
Evaluate the expected performance of Guardant Health (GH) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2024-11-05 12:20:40 |
Czytaj oryginał (ang.) |
| Why Guardant Health Stock Was the Picture of Health Today |
There's nothing like free publicity to help goose the sales of a relatively new product. |
fool.com |
2024-10-30 20:52:00 |
Czytaj oryginał (ang.) |
| Will Guardant Health (GH) Report Negative Earnings Next Week? What You Should Know |
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-30 13:07:54 |
Czytaj oryginał (ang.) |
| Guardant Health Named to TIME's List of the Best Inventions of 2024 |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the inclusion of its blood-based colorectal cancer screening product Shield in TIME's annual list of the Best Inventions, which features 200 extraordinary innovations changing lives. To compile this year's list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing. |
businesswire.com |
2024-10-30 11:30:00 |
Czytaj oryginał (ang.) |
| Roberto A. Mignone Joins Guardant Health Board of Directors |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. “We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long. |
businesswire.com |
2024-10-24 21:05:00 |
Czytaj oryginał (ang.) |
| GameHost Announces Regular Monthly Dividend for October |
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. RED DEER, AB / ACCESSWIRE / October 17, 2024 / Gamehost Inc. (‘Gamehost', the ‘Company') (TSX:GH) has declared a cash dividend for the month of October 2024 of $0.04 (CDN) per common share, which equates to $0.48 (CDN) per common share on an annualized basis. The dividend will be paid on November 15, 2024 to shareholders of record on October 31, 2024. |
accesswire.com |
2024-10-17 21:00:00 |
Czytaj oryginał (ang.) |
| Guardant Health to Report Third Quarter 2024 Financial Results on November 6, 2024 |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2024 after market close on Wednesday, November 6, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast wi. |
businesswire.com |
2024-10-15 20:05:00 |
Czytaj oryginał (ang.) |
| Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types |
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial. |
businesswire.com |
2024-09-13 06:00:00 |
Czytaj oryginał (ang.) |